What is Surrozen, Inc. (SRZN) stock price today?

Surrozen, Inc. (SRZN) is currently trading at $29.69, up 6.15% today.

What is SRZN P/E ratio?

Surrozen, Inc.'s P/E ratio is -0.60. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SRZN return on equity (ROE)?

Surrozen, Inc.'s return on equity (ROE) is 187.62%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Surrozen, Inc.'s market cap?

Surrozen, Inc. has a market capitalization of $222.00M.

NASDAQ · Biotechnology

Surrozen, Inc. (SRZN) Stock

$29.69 +6.15% NASDAQ: SRZN Healthcare

Valuation

Metric	Value
Price	$29.69
Market Cap	$222.00M
P/E Ratio	-0.60
P/B Ratio	-1.33
P/S Ratio	16.14
EPS (TTM)	$-32.37
52-Week High	$37.83
52-Week Low	$11.39
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	187.62%
ROA	-287.29%
ROCE	-41.61%
Gross Margin	-1433.33%
Operating Margin	-1400.00%
Net Margin	-45.71%
Debt/Equity	-0.03
Current Ratio	9.20

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$13.0M	$0	$11.0M	$3.0M
Operating Profit	$-54.0M	$-44.0M	$-46.0M	$-26.0M	$-42.0M
Net Profit	$-53.0M	$-36.0M	$-43.0M	$-64.0M	$-242.0M
EPS	$-23.40	$-15.55	$-21.33	$-21.67	$-32.37
Op Margin	—	-354.7%	—	-239.7%	-1210.6%

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$137.0M	$89.0M	$46.0M	$48.0M	$99.0M
Total Liabilities	$27.0M	$13.0M	$8.0M	$70.0M	$286.0M
Cash	$33.0M	$25.0M	$36.0M	$35.0M	$89.0M
Borrowings	$8.0M	$6.0M	$3.0M	$8.0M	$7.0M

Latest News

Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright MarketBeat · Jul 22, 2026 Surrozen to Present at Upcoming Healthcare Investor Conference GlobeNewswire · Jul 15, 2026 We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate Simply Wall St. · May 17, 2026 Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update GlobeNewswire · May 6, 2026 Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Apr 28, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-49.0M	$-44.0M	$-40.0M	$-18.0M	$-30.0M
Investing Cash Flow	$-79.0M	$38.0M	$51.0M	$0	$0
Financing Cash Flow	$0	$-3.0M	$0	$0	$0
Net Cash Flow	$-2.0M	$-8.0M	$12.0M	$-1.0M	$55.0M
Free Cash Flow	$-50.0M	$-45.0M	$-41.0M	$-18.0M	$-30.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.01
EV / EBITDA	-0.27
FCF Yield	-18.83%
Quick Ratio	12.14
Interest Coverage	0.00
Return 1Y	154.12%
Return 3Y	97.38%
Return 5Y	-85.33%

Ownership

Insiders Held3.18%

Institutions Held102.83%

Institutions Float Held106.20%

Institutional Holder	Shares	Report Date
Column Group LLC	1,916,950	2026-03-31
TCG Crossover Management, LLC	1,473,101	2026-03-31
Boxer Capital Management, LLC	766,318	2026-03-31
Millennium Management Llc	731,138	2026-03-31
Venrock Adviser, LLC	632,931	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AGENAgenus Inc.	$7.67	+1.72%	3.66	$319.40M	0.00%
ATOSAtossa Therapeutics, Inc.	$2.44	+0.83%	-0.54	$24.34M	0.00%
CGTXCognition Therapeutics, Inc.	$0.88	-2.04%	-4.82	$78.48M	0.00%
GLSIGreenwich LifeSciences, Inc.	$16.53	+9.18%	-11.03	$242.63M	0.00%
IMMXImmix Biopharma, Inc.	$9.46	+1.83%	-11.00	$514.64M	0.00%

About Surrozen, Inc.

Surrozen, Inc. is led by CEO Craig C. Parker, employs 40 people, headquartered in US, publicly traded since 2021.

Surrozen, Inc. (SRZN) stock trades at $29.69 with a market capitalization of $222.00M. The stock is valued at a price-to-earnings (P/E) ratio of -0.60, price-to-book of -1.33, price-to-sales of 16.14. Over the past 52 weeks the stock has ranged between $11.39 and $37.83, and currently trades 21.5% below its 52-week high.

On profitability, Surrozen, Inc. generates a return on equity (ROE) of 187.62% — well above the market average, a sign of a high-quality business, return on capital employed of -41.61%, an operating margin of -1400.00%, a net profit margin of -45.71%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides